Navigation Links
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
Date:12/7/2009

SAN DIEGO, Dec. 7 /PRNewswire/ -- Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

The open-label, dose-escalation study, "AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Phase I AML Study," was designed to evaluate the safety, tolerability, and pharmacokinetic profile of AC220 in AML patients with predominantly relapsed or refractory disease. AC220 was generally well-tolerated in AML patients, and importantly, there was no treatment-related mortality observed in this study. Clinical response and median survival were assessed as secondary endpoints and analyzed for the overall study population, in addition to patient subsets based on the presence or absence of the FLT3 genotype for the internal tandem duplication (ITD) mutation (FLT3 ITD+ and FLT3 ITD-, respectively). Following treatment with AC220, responses were observed in both FLT3 ITD+ and FLT3 ITD- patients, and responders in each group had at least a doubling in median survival versus non-responders.

"AML represents a challenging hematological malignancy to treat. A significant portion of AML patients have activating FLT3 mutations, and these patients have a particularly poor prognosis and are often refractory to current treatment options," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, and primary investigator for the Phase I Study. "These encouraging results with AC220 warrant further studies of this promising
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... CHAPEL HILL, N.C. , Oct. 24, 2014 ... Consortium to provide Medical Affairs leaders with a ... they face. The consortium has developed a mechanism ... roundtable discussions where leaders discuss key findings from ... Best Practices has completed the analysis for the ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Quest Diagnostics ... of diagnostic information services, today announced that its Board ... serve as a director, effective December 1, 2014. Including ... Dr. Leiden is the Chairman, President and CEO of ... years of scientific and commercial experience in the pharmaceutical ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ready ... trackers for themselves and their kids, according to the ... Health & Fitness Go Mobile for Moms, the latest ... BabyCenter, the number 1 pregnancy and parenting web and ... 55 percent of moms surveyed say they can,t think ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4
... Feb. 24, 2011 Reportlinker.com announces that a new ... Global Drug-Eluting Stents Industry ... analyzes the worldwide markets for Drug-Eluting Stents in US$ ... US, Japan, Europe, and Rest of World. Annual estimates ...
... West Pharmaceutical Services, Inc. (NYSE: WST ) ... of the Board to twelve and appointed two new directors, ... of their terms are effective immediately and will expire at ... for election to serve for the balance of their terms. ...
Cached Medicine Technology:Reportlinker Adds Global Drug-Eluting Stents Industry 2West Appoints Two Directors and Announces Second Quarter 2011 Dividend 2
(Date:10/25/2014)... York, NY (PRWEB) October 26, 2014 ... treatments, announces the most advanced and improved laser treatments ... effective and safe treatments like the lip enhancement ... in keeping with specific focus areas of each customer. ... like cellulite reduction NYC . The company cited ...
(Date:10/25/2014)... -- Arriving home safe and sound is one of the ... sure that costumes and goody bags have reflective strips that ... medicine doctor at Meadowlands Hospital Medical Center in Secaucus, N.J. ... should be flame-resistant, Davis said. He offers these others ... it on a small area of skin first to ensure ...
(Date:10/25/2014)... 25, 2014 TASC (Total Administrative ... other benefits account management services, announces the release ... save on taxes, reduce administrative workload, and lessen ... savings and the efficient handling of complex, time-sensitive, ... that best meets their goals and objectives. The ...
(Date:10/25/2014)... 2014 QueenBeeTickets.com has a variety of ... at affordable prices. Bob Seger & The Silver Bullet ... Nationwide Arena are going on sale October 25 and ... to browse the selection of tickets for Bob ... The famous singer is touring North America beginning next ...
(Date:10/25/2014)... 2014 Mesothelioma researchers are reporting extended ... pemetrexed (Alimta), after his combination drug therapy became too ... , just posted on the Surviving Mesothelioma website. ... Center in Japan suggests that “maintenance therapy” with pemetrexed ... who cannot tolerate higher doses of cisplatin. , ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:Tips for Safe Trick-or-Treating 2Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2
... ... every year, 35 to 50 million Americans become infected with the flu (influenza). On average, ... Plano, TX is taking steps to combat these preventable deaths by offering free flu shots ... Plano, TX (Vocus) September 12, ...
... , , , ... important safety notice to its more than 750,000 subscribers of its ... wearing a "pendant" style help button. The service is used primarily ... at risk of falls. By pressing a "help button" worn on ...
... of Public Health has been awarded $18.4 million by ... U.S. Department of Defense to establish an Extremity Trauma ... the coordinating center for the Consortium that includes a ... with several major military treatment centers and the U.S. ...
... ... on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- PAINWeek® 2009, the national conference ... drug reform in the United States as keynote speaker former Assistant US Attorney Jennifer Bolen, ...
... help predict who,s susceptible to the disease, study says , ... to a higher risk of Alzheimer,s disease seems to affect ... thought, new research suggests. , The brains of people in ... -- which boosts the risk of Alzheimer,s but doesn,t guarantee ...
... , NEW YORK, Sept. 11 Duane Reade Holdings ... that, as the Local Presenting Sponsor of the 2009 Komen New ... its foundation, The Duane Reade Charitable Foundation, have raised $330,000 to ... to find a cure. This marks the third year that Duane ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Lifeline Issues Safety Notice to Subscribers 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Alzheimer's Gene Affects Brains of Young Adults 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... a fast, precise patternless edge for a ... TOPCON ALE-X1. The latest advance in lens ... features and functions. High-speed processing, a diamond ... edges, precise three-dimensional frame tracing via the ...
Inquire...
Inquire...
Medicine Products: